Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF0166 in Diabetic Macular Edema
NCT02914613Phase 2Completed
- Sponsor
- OcuTerra Therapeutics
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nesvategrast in diabetic macular edema (DME) (2 arms), sponsored by OcuTerra Therapeutics. Primary endpoints: Number of Subjects With No Cells Observed Following Slit Lamp Examination at 8 weeks, Number of Subjects With Flare Observed Following Slit Lamp Examination at 8 weeks and 14 more. Started Aug 2016; status: completed.
02
Drugs
nesvategrast
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02914613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914613.